期刊文献+

干扰素诱导的MxA蛋白及其抗丙型肝炎病毒感染作用的研究进展

Progress in Research on Interferon-induced MxA and Its Therapeutic Effect on Hepatitis C Virus Infection
原文传递
导出
摘要 干扰素α(Interferon α,IFNα)是目前公认的可有效抗丙型肝炎病毒(Hepatitis C virus,HCV)的药物,其主要通过诱导细胞产生抗病毒蛋白而发挥作用。抗黏病毒蛋白A(Mixovirus resistance protein A,MxA)是由I型IFN诱导产生的相对分子质量为78000的抗病毒蛋白,主要分布于细胞质中,具有识别HCV核糖核蛋白复合物(Virus ribonucleoprotein complexes,vRNPs)的功能,通过MxA的GTP酶活性水解HCV核衣壳,使病毒核酸释放并被胞浆中的核酸内切酶降解。本文主要对IFN的分类、MxA的结构和作用机制及近年来MxA抗HCV感染作用的研究进展作一综述。 Interferon α has been proven to be effective in the treatment of hepatitis C virus(HCV)infection. This therapeutic effect is reached by IFN-induced antiviral cellular proteins. Mixovirus resistance protein A (MxA), with a relative molecular mass of 78 000, is one of the cellular proteins induced by type I interferon. As an antiviral protein,MxA accumulates to high levels in the cytoplasm of interferon-treated cells. MxA tightly interacts with components of the virus ribonucleoprotein complexes (vRNPs)of HCV, and hydrolyzes HCV nuclocapsid by its GTPase activity,which makes virus nucleic acid release and be digested by host cell endonuclease. This review focuses the recent progress in research on the classification of IFN, the structure of MxA as well as the therapeutic effect of MxA on hepatitis C virus infection.
出处 《中国生物制品学杂志》 CAS CSCD 2010年第10期1141-1143,1152,共4页 Chinese Journal of Biologicals
基金 国家传染病重大专项课题(2008ZX10002-013) 军队后勤科研项目(08A) 上海市重点学科建设项目(B901) 上海市医学生物防护重点实验室开放课题资助
关键词 干扰素Α 抗黏病毒蛋白A 丙型肝炎病毒 Interferon α Mixovirus resistance protein A Hepatitis C virus
  • 相关文献

参考文献31

  • 1Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors [J]. Immunol Rev, 2004, 202( 1 ):8-32.
  • 2Martal JL, Chene NM, Huynh LP, et al. IFN-tau:a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relations'hips, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities [J]. Biochimie. 1998, 80 (8-9) :755 -777.
  • 3LaFleur DW, Nardelli B, Tsareva T, et al. Interferon-kappa, a novel type 1 interferon expressed in human keratinocyies [J]. J Biol Chem, 2001, 276 (43) : 39765-39771.
  • 4Chen J, Baig E, Fish EN. Diversity and relatedness among the type I interferons [J]. J Interferon Cytokine Res, 2004, 24 ( 12):687-698.
  • 5Sheppard P, Kindsvogel W, Xu W. et al. IL-28,IL.-29 and their class II cytokine receptor IL-28R [J]. Nat Immunol, 2003,4(1): 63-68.
  • 6Dumoutier L, Lejeune D, Hor S, et al. Chining of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)I, STAT2 and STAT3 [J]. Biochem J, 2003, 370 (Pt 2):391-396.
  • 7Mogensen KE, Lewerenz M, Reboul J, et al. The type I interferon receptor:structure, function, and evolution of a family business [J]. J Interferon Cytokine Res, 1999, 19 (10) : 1069-1098.
  • 8Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor:a paradigm for cytokine receptor signaling [J]. Annu Rev Immunol, 1997, 15:563-59l.
  • 9Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex [J]. Nat Immunol, 2003, 4 ( 1 ) :69-77.
  • 10Taylor JL, Grossberg SE. Recent progress in interferon research: molecular mechanisms of regulation, action and virus circumvention [J]. Virus Res, 1990, 15(1):1-25.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部